NCT00267826View on ClinicalTrials.gov

Immunopharmacological Effects of Rituximab in Atopic Dermatitis

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

December 31, 2006

Conditions
Dermatitis, Atopic
Interventions
DRUG

Rituximab

Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis

Trial Locations (1)

CH-3010

University of Bern, Department of Dermatology, Bern

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Swiss National Science Foundation

OTHER

lead

University of Bern

OTHER

NCT00267826 - Immunopharmacological Effects of Rituximab in Atopic Dermatitis | Biotech Hunter | Biotech Hunter